FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124013844> ?p ?o ?g. }

• W2124013844 endingPage "3876" @default.
• W2124013844 startingPage "3869" @default.
• W2124013844 abstract "Complete remission and long-term survival rates are low for older adults treated for acute myeloid leukemia (AML). Because of favorable phase 2 data using mitoxantrone and etoposide, we conducted a phase 3 study (SWOG-9333) in which patients over 55 years of age with previously untreated AML were randomized to receive mitoxantrone (10 mg/m2 per day × 5) and etoposide (100 mg/m2per day × 5) [ME], or cytarabine (200 mg/m2 per day × 7) and daunorubicin (45 mg/m2 per day × 3) [AD] as induction therapy. The randomization was stratified by age, onset of leukemia, and multidrug resistance phenotype. Over a 4-year period, 328 eligible patients from 66 institutions were enrolled. The complete remission rate was 34% (95% confidence interval [CI] 26%-41%) for patients in the ME and 43% (CI 35%-51%) for patients in the AD treatment arm (one-tailedP value .96). The rates of resistant disease were 43% (CI 35%-51%) and 34% (CI 27%-42%), respectively, for the 2 treatment arms (one-tailed P value .95). The estimated overall survival at 2 years was 11% (CI 6%-15%) and 19% (CI 12%-25%) for patients randomized to ME and to AD induction therapy, respectively (one-tailed P value .99). After accounting for the independent prognostic factors associated with survival (karyotype, performance status, age, white blood cell count), exploratory analysis suggested there was a worse survival for patients who received ME compared with AD induction therapy (2-tailed P value .0066). We conclude that the results of our study do not demonstrate any benefit to the use of ME induction chemotherapy instead of AD in older patients with AML." @default.
• W2124013844 created "2016-06-24" @default.
• W2124013844 creator A5005996885 @default.
• W2124013844 creator A5013596178 @default.
• W2124013844 creator A5013640001 @default.
• W2124013844 creator A5037739026 @default.
• W2124013844 creator A5046605612 @default.
• W2124013844 creator A5056405520 @default.
• W2124013844 creator A5058365130 @default.
• W2124013844 creator A5061732223 @default.
• W2124013844 creator A5067752037 @default.
• W2124013844 creator A5076620546 @default.
• W2124013844 creator A5083011083 @default.
• W2124013844 date "2002-12-01" @default.
• W2124013844 modified "2023-10-17" @default.
• W2124013844 title "Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study" @default.
• W2124013844 cites W118967028 @default.
• W2124013844 cites W1492445977 @default.
• W2124013844 cites W1492609361 @default.
• W2124013844 cites W1519562949 @default.
• W2124013844 cites W1586763410 @default.
• W2124013844 cites W1919339218 @default.
• W2124013844 cites W1963335440 @default.
• W2124013844 cites W1990189905 @default.
• W2124013844 cites W2000275771 @default.
• W2124013844 cites W2015941559 @default.
• W2124013844 cites W2039082386 @default.
• W2124013844 cites W2052735722 @default.
• W2124013844 cites W2077902415 @default.
• W2124013844 cites W2087038588 @default.
• W2124013844 cites W2115587079 @default.
• W2124013844 cites W2152363012 @default.
• W2124013844 cites W2201158929 @default.
• W2124013844 cites W2204518675 @default.
• W2124013844 cites W2222947433 @default.
• W2124013844 cites W2315152253 @default.
• W2124013844 cites W2318674152 @default.
• W2124013844 cites W27031567 @default.
• W2124013844 cites W2764775166 @default.
• W2124013844 cites W4237785786 @default.
• W2124013844 cites W4239564692 @default.
• W2124013844 cites W4253003234 @default.
• W2124013844 cites W4253916874 @default.
• W2124013844 cites W4293241248 @default.
• W2124013844 cites W4302772633 @default.
• W2124013844 doi "https://doi.org/10.1182/blood-2001-12-0354" @default.
• W2124013844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12393614" @default.
• W2124013844 hasPublicationYear "2002" @default.
• W2124013844 type Work @default.
• W2124013844 sameAs 2124013844 @default.
• W2124013844 citedByCount "185" @default.
• W2124013844 countsByYear W21240138442012 @default.
• W2124013844 countsByYear W21240138442013 @default.
• W2124013844 countsByYear W21240138442014 @default.
• W2124013844 countsByYear W21240138442015 @default.
• W2124013844 countsByYear W21240138442016 @default.
• W2124013844 countsByYear W21240138442017 @default.
• W2124013844 countsByYear W21240138442018 @default.
• W2124013844 countsByYear W21240138442019 @default.
• W2124013844 countsByYear W21240138442020 @default.
• W2124013844 countsByYear W21240138442021 @default.
• W2124013844 countsByYear W21240138442022 @default.
• W2124013844 countsByYear W21240138442023 @default.
• W2124013844 crossrefType "journal-article" @default.
• W2124013844 hasAuthorship W2124013844A5005996885 @default.
• W2124013844 hasAuthorship W2124013844A5013596178 @default.
• W2124013844 hasAuthorship W2124013844A5013640001 @default.
• W2124013844 hasAuthorship W2124013844A5037739026 @default.
• W2124013844 hasAuthorship W2124013844A5046605612 @default.
• W2124013844 hasAuthorship W2124013844A5056405520 @default.
• W2124013844 hasAuthorship W2124013844A5058365130 @default.
• W2124013844 hasAuthorship W2124013844A5061732223 @default.
• W2124013844 hasAuthorship W2124013844A5067752037 @default.
• W2124013844 hasAuthorship W2124013844A5076620546 @default.
• W2124013844 hasAuthorship W2124013844A5083011083 @default.
• W2124013844 hasBestOaLocation W21240138441 @default.
• W2124013844 hasConcept C126322002 @default.
• W2124013844 hasConcept C141071460 @default.
• W2124013844 hasConcept C143998085 @default.
• W2124013844 hasConcept C168563851 @default.
• W2124013844 hasConcept C204243189 @default.
• W2124013844 hasConcept C2776611710 @default.
• W2124013844 hasConcept C2776694085 @default.
• W2124013844 hasConcept C2778041864 @default.
• W2124013844 hasConcept C2778119113 @default.
• W2124013844 hasConcept C2778336483 @default.
• W2124013844 hasConcept C2778729363 @default.
• W2124013844 hasConcept C2780923524 @default.
• W2124013844 hasConcept C2781021840 @default.
• W2124013844 hasConcept C71924100 @default.
• W2124013844 hasConcept C90924648 @default.
• W2124013844 hasConceptScore W2124013844C126322002 @default.
• W2124013844 hasConceptScore W2124013844C141071460 @default.
• W2124013844 hasConceptScore W2124013844C143998085 @default.
• W2124013844 hasConceptScore W2124013844C168563851 @default.
• W2124013844 hasConceptScore W2124013844C204243189 @default.
• W2124013844 hasConceptScore W2124013844C2776611710 @default.
• W2124013844 hasConceptScore W2124013844C2776694085 @default.

• next